Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma

Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma

Saved in:

Bibliographic Details
Main Authors:	Asis Shrestha, Anup Kumar Trikannad Ashwini Kumar, Soumya Pandey, Tanvi Patel, Hira Imad Cheema, Syed Mujtaba Naqvi, Ramya Bachu, Trilok Shrivastava, Sharmilan Thanendrarajan, Maurizio Zangari, Samer Al Hadidi, Frits van Rhee, Carolina Schinke
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-04-01
Series:	Frontiers in Hematology
Subjects:	immune thrombocytopenia Teclistamab BCMA multiple myeloma plasma cells
Online Access:	https://www.frontiersin.org/articles/10.3389/frhem.2025.1547209/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Injection site reaction to teclistamab in a patient with multiple myeloma
by: Isabel C. Yoon, BS, et al.
Published: (2025-02-01)

Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis
by: Wenze Li, et al.
Published: (2025-04-01)

Case Report: Reactive T-cell large granular lymphocytes in the bone marrow of a patient with relapsed/refractory multiple myeloma receiving teclistamab
by: Erin A. Dean, et al.
Published: (2025-08-01)

A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
by: Alfred L. Garfall, et al.
Published: (2025-07-01)

Belantamab Mafodotin Monotherapy for Multiply‐Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland
by: Edmund C. R. Watson, et al.
Published: (2025-06-01)

Netrin‐1 and B‐cell maturation antigen expression in a large cohort of 361 lymphomas: sensitive and specific staining in plasmablastic lymphomas, and therapeutic perspectives
by: Marie Donzel, et al.
Published: (2025-05-01)

BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting
by: Huijian Zheng, et al.
Published: (2025-03-01)

BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma
by: Chengwei Jin, et al.
Published: (2025-12-01)

T-Cell Engagers In Multiple Myeloma: A Clinical Review
by: Al-Jarrad A, et al.
Published: (2025-03-01)

CCN1 promotes APRIL/BAFF signaling in esophageal squamous cell carcinoma but attenuates it in esophageal adenocarcinoma
by: Lingling Xing, et al.
Published: (2025-01-01)

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
by: Meera Mohan, et al.
Published: (2025-04-01)

Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma
by: Lili Zhou, et al.
Published: (2025-05-01)

Quantification of total sBCMA in human plasma by peptide-level immunocapture LC-MS/MS
by: Johanna Paris, et al.
Published: (2025-04-01)

Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma
by: Ning An, et al.
Published: (2025-05-01)

Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma
by: Brandon Tedder, et al.
Published: (2025-07-01)

Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report
by: Chiara Bernardi, et al.
Published: (2024-11-01)

Increased serum B‐cell maturation antigen levels evaluated with an Elecsys‐based serum B‐cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma
by: Evangelos Terpos, et al.
Published: (2025-02-01)

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
by: Yuhan Yan, et al.
Published: (2024-11-01)

CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives
by: Jincai Zhou, et al.
Published: (2024-12-01)

BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial
by: Hao Yao, et al.
Published: (2025-05-01)

Manifestations of Teclistamab‐Associated Uveitis
by: Gabriel Castilho Barbosa, et al.
Published: (2025-06-01)

Prevalence of CCR7‐Positive CD8 T Cells as a Prognostic Factor in B‐Cell Maturation Antigen ‐Targeted Chimeric Antigen Receptor T Cell Therapy
by: Yoshiaki Marumo, et al.
Published: (2025-06-01)

TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model
by: Aina Oliver-Caldes, et al.
Published: (2025-12-01)

Case Report: Summary of multiple CAR-T expansions in anti-BCMA/GPRC5D bispecific CAR-T cell therapy for multiple myeloma
by: Liya Wei, et al.
Published: (2025-06-01)

Potent anti‐tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma
by: Felix Oden, et al.
Published: (2015-08-01)

Eculizumab for Hyperhemolysis in Sickle Cell Disease: Key Insights From a Challenging Case
by: Sruthi Vellanki, et al.
Published: (2024-12-01)

Teclistamab for heavily pretreated relapsed / refractory POEMS syndrome
by: Alexis Talbot, et al.
Published: (2025-07-01)

Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients
by: Farheen Chunara, et al.
Published: (2025-04-01)

MONITORAMENTO DOS EFEITOS ADVERSOS DO TECLISTAMABE: PAPEL DA ENFERMAGEM
by: VMS Moraes, et al.
Published: (2024-10-01)

Teclistamab‐Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma
by: Renata Quevedo‐Salazar, et al.
Published: (2025-06-01)

Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment
by: Danai Dima, et al.
Published: (2025-07-01)

Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma
by: James A. Davis, et al.
Published: (2025-03-01)

Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice
by: Wen Ling, et al.
Published: (2025-06-01)

Risk factors and clinical impact of cytomegalovirus DNAemia in patients with multiple myeloma treated with teclistamab
by: Charles Pei, et al.
Published: (2025-08-01)

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
by: Carlyn Rose Tan, et al.
Published: (2025-04-01)

Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
by: Carlyn Rose Tan, et al.
Published: (2025-07-01)

Sequential Myelomatous Pleural and Pericardial Effusions in Multiple Myeloma: A Case Report Demonstrating Extended Survival with Teclistamab
by: Deena Mudawi, et al.
Published: (2025-05-01)

WCN25-1014 TECLISTAMAB AND NIVOLUMAB: A SYNERGISTIC KIDNEY STORM - A CASE OF ACUTE INTERSTITIAL NEPHRITIS WITH DUAL IMMUNOTHERAPY
by: Arjunmohan Mohan, et al.
Published: (2025-02-01)

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
by: Oren Pasvolsky, et al.
Published: (2025-05-01)

Teclistamab <i>versus</i> B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis
by: Junmin Song, et al.
Published: (2025-04-01)